{"id":"adjunctive-asenapine","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Akathisia"},{"rate":"8-12","effect":"Somnolence"},{"rate":"5-10","effect":"Weight gain"},{"rate":"5-8","effect":"Extrapyramidal symptoms"},{"rate":"4-7","effect":"Dizziness"},{"rate":"3-5","effect":"Oral hypoesthesia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Asenapine acts as an antagonist at multiple dopamine receptors (D2, D3) and serotonin receptors (5-HT2A, 5-HT7), with particular affinity for D2 and 5-HT2A. When used adjunctively, it enhances the therapeutic effect of other psychiatric medications by providing additional dopaminergic and serotonergic modulation, helping to stabilize mood and reduce psychotic or manic symptoms in patients with inadequate response to monotherapy.","oneSentence":"Asenapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:20.203Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment of bipolar I disorder in adults"},{"name":"Adjunctive treatment of major depressive disorder in adults"}]},"trialDetails":[{"nctId":"NCT01587118","phase":"PHASE4","title":"An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder","status":"COMPLETED","sponsor":"Lori Davis, MD","startDate":"2012-06","conditions":"Posttraumatic Stress Disorder","enrollment":18},{"nctId":"NCT01670019","phase":"PHASE4","title":"Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression","status":"COMPLETED","sponsor":"Duke University","startDate":"2012-10","conditions":"Major Depressive Disorder Without Psychotic Features","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["asenapine","Saphris"],"phase":"marketed","status":"active","brandName":"Adjunctive asenapine","genericName":"Adjunctive asenapine","companyName":"Lori Davis, MD","companyId":"lori-davis-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Asenapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances. Used for Adjunctive treatment of bipolar I disorder in adults, Adjunctive treatment of major depressive disorder in adults.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2010-09-01T00:00:00.000Z","mah":"Organon N.V.","brand_name_local":"Sycrest","application_number":"EMEA/H/C/001177"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-10-11T00:00:00.000Z","mah":"HISAMITSU","brand_name_local":"SECUADO","application_number":"NDA212268"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}